NCT03672097View on ClinicalTrials.gov

Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)

PHASE4CompletedINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions

Acute Coronary Syndrome (ACS)

Interventions

DRUG

Prasugrel

Prasugrel, oral tablets, containing 3.75 mg per tablet

Trial Locations (10)

Unknown

Kaohsiung Veterans General Hospital, Kaohsiung City

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

Cheng Hsin General Hospital, Taipei

Mackay Memorial Hospital, Taipei

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei

Chang Gung Memorial Hospital, Linkou, Taoyuan District

All Listed Sponsors

lead

Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

INDUSTRY

NCT03672097 - Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) | Biotech Hunter | Biotech Hunter